These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies. Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519 [TBL] [Abstract][Full Text] [Related]
17. Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry. Itai S; Kaneko MK; Fujii Y; Yamada S; Nakamura T; Yanaka M; Saidoh N; Handa S; Chang YW; Suzuki H; Harada H; Kato Y Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):214-219. PubMed ID: 28891752 [TBL] [Abstract][Full Text] [Related]
18. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity. Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976 [TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223 [TBL] [Abstract][Full Text] [Related]
20. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]